Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Clin Oncol. 2002 Feb;25(1):96-100.

Gemcitabine-induced pulmonary toxicity: case report and review of the literature.

Author information

1
Division of Hematology/Oncology, Department of Medicine, Long Island Jewish Medical Center, 270-05 76 Avenue, New Hyde Park, NY 11042, U.S.A.

Abstract

Gemcitabine is a pyrimidine analog with a similar chemical structure and mechanism of action, as cytarabine. It has been shown to be a highly active agent for non-small cell lung cancer, pancreatic cancer, urothelial cancer, breast cancer and ovarian cancer. Gemcitabine is relatively well tolerated and myelosuppression is the dose-limiting toxicity. Pulmonary toxicity with gemcitabine is relatively uncommon, but a well recognized entity, associated with significant morbidity and mortality. A high index of suspicion, early diagnosis and timely intervention with oxygen supplementation, steroids, and diuretics is necessary to manage patients with this complication.

PMID:
11823707
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer
    Loading ...
    Support Center